Across TCGA pan-cancer cohorts, ASB7 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ASB7 data layer compared with 20 for mass-spec protein and 3 for mass-spec protein.
The strongest signal is observed in esophageal carcinoma (ESCA), where higher ASB7 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ASB7 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
ESCA, COAD, and LUSC are the cancer types where ASB7 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.